ABCG2 and ovarian carcinoma: Furthermore, despite several in vitro studies of ABCG2 involvement in drug efflux and drug resistance, recent in vivo data showed no connection between ABCG2 expression and drug resistance [38] as well as no relationship between a patient ́s progression-free survival or overall survival and level of ABCG2 expression in ovarian carcinoma patients [37].